U.S. Markets close in 5 hrs 8 mins

DURECT Corporation (DRRX)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.55+0.01 (+0.97%)
As of 10:52AM EDT. Market open.
People also watch
PTIEARQLDEPOCPRXGTXI
Full screen
Previous Close1.54
Open1.56
Bid1.53 x 2600
Ask1.54 x 300
Day's Range1.51 - 1.56
52 Week Range0.74 - 2.00
Volume112,887
Avg. Volume982,317
Market Cap220.76M
Beta2.28
PE Ratio (TTM)-6.00
EPS (TTM)-0.26
Earnings DateJul 31, 2017 - Aug 4, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.42
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR®

    CUPERTINO, Calif., June 22, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial of POSIMIR® (SABER®-Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. In May 2017, DURECT signed a development and commercialization agreement with Sandoz AG, a division of Novartis, covering the United States.  Under the terms of the agreement, Sandoz made an upfront payment to DURECT of $20 million following review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales-based milestones, as well as a tiered double-digit royalty on product sales in the United States.  DURECT remains responsible for the completion of the ongoing PERSIST Phase 3 clinical trial for POSIMIR as well as FDA interactions through approval.

  • Accesswire7 days ago

    Featured Company News - DURECT-SANDOZ Collaboration Clears HSR Review; Paves Path for POSIMIR Development and Marketing in the U.S.

    Research Desk Line-up: Taro Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 21, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for DURECT ...

  • PR Newswire9 days ago

    DURECT's Collaboration with Sandoz Clears HSR Review and is Effective

    CUPERTINO, Calif., June 19, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery, has cleared review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and has become effective. Under the terms of the agreement, Sandoz has made an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales-based milestones, as well as a tiered double-digit royalty on product sales in the United States.